Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Gram Peptides

Has Gram Peptides received an FDA warning letter? Yes. FDA issued a warning letter dated March 31, 2026 concerning products containing retatrutide and tirzepatide.

Letter facts

Letter date
March 31, 2026 (2026-03-31)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Online / Internet Pharmacy
Products named
Retatrutide (marketed as GLP-1-R peptide)Tirzepatide (marketed as GLP-2 peptide)Bacteriostatic Water for Injection
Violation categories
Unapproved new drug

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Factual Violation Summary

FDA says the website offered Retatrutide, Tirzepatide, and Bacteriostatic Water for Injection with labeling showing intended human drug use; no approved applications exist, so products are unapproved new drugs introduced into interstate commerce.

Statutory Citations & Specific Allegations

  • Unapproved new drug (FD&C Act section 505(a))
  • Introduction/delivery into interstate commerce (sections 301(d) and 505(a))
  • Drug intended for human use despite Research Use Only labeling

More letters about Retatrutide

Recent FDA warning letters concerning Retatrutide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.